A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil or ALKS 9070) in Subjects With Schizophrenia

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Alkermes
ClinicalTrials.gov Identifier:
NCT01469039
First received: November 8, 2011
Last updated: March 21, 2014
Last verified: March 2014
  Purpose

The study will determine the efficacy of ALKS 9072 (also known as ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.


Condition Intervention Phase
Schizophrenia
Drug: ALKS 9072
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia

Resource links provided by NLM:


Further study details as provided by Alkermes:

Primary Outcome Measures:
  • Positive and Negative Syndrome Scale (PANSS) total score [ Time Frame: 85 Days ] [ Designated as safety issue: No ]
    Change from baseline to Day 85


Secondary Outcome Measures:
  • Clinical Global Impression - Improvement (CGI-I) Scores [ Time Frame: 85 Days ] [ Designated as safety issue: No ]

Enrollment: 623
Study Start Date: December 2011
Estimated Study Completion Date: March 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ALKS 9072 Drug: ALKS 9072
Intramuscular (IM) injection, 300 mg or 600 mg given monthly
Placebo Comparator: Placebo Drug: Placebo
Placebo for IM injection, given monthly

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia according to DSM-IV-TR criteria
  • Has been able to achieve outpatient status for more than 3 months in the past year
  • Body mass index (BMI) of 18.5 to 40.0 kg/m2 (inclusive)
  • Resides in a stable living situation
  • Willing and able to be confined to an inpatient study unit for 2 weeks or longer

Exclusion Criteria:

  • History of poor or inadequate clinical response to treatment with aripiprazole
  • History of treatment resistance
  • Known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its ingredients, other antipsychotic agent, or INTRALIPID (including peanuts, soy, egg, or glycerol)
  • Diagnosis of current substance dependence (including alcohol)
  • Pregnant, lactating, or breastfeeding
  • Receipt of any antipsychotic medication by IM injection within 60 days before Screening
  • Current involuntary hospitalization or incarceration
  • Hospitalized for more than 30 days during the 90 days before Screening

Additional inclusion/exclusion criteria may apply.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01469039

  Show 84 Study Locations
Sponsors and Collaborators
Alkermes
Investigators
Study Director: Robert Risinger, MD Alkermes
  More Information

Additional Information:
No publications provided

Responsible Party: Alkermes
ClinicalTrials.gov Identifier: NCT01469039     History of Changes
Other Study ID Numbers: ALK9072-003
Study First Received: November 8, 2011
Last Updated: March 21, 2014
Health Authority: United States: Food and Drug Administration
Bulgaria: Bulgarian Drug Agency
Malaysia: Ministry of Health
Philippines: Department of Health
Romania: National Medicines Agency
Russia: Ministry of Health of the Russian Federation
Ukraine: Ministry of Health
Korea: Ministry of Food and Drug Safety

Keywords provided by Alkermes:
Alkermes
schizophrenia
ALKS 9072
ALKS 9070
aripiprazole lauroxil

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Aripiprazole
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on April 15, 2014